Abstract
Dysregulation of the Akt/PKB pathway has been associated with poor prognosis in several human carcinomas. Current approaches to assess Akt activation rely on intensity-based methods, which are limited by the subjectivity of manual scoring and poor specificity. Here, we report the development of a novel assay using amplified, time-resolved Förster resonance energy transfer (FRET), which is highly specific and sensitive and can be adapted to any protein. Using this approach to analyze primary breast tissue microarrays, we quantified levels of activated pAkt at a spatial resolution that revealed molecular heterogeneity within tumors. High pAkt status assessed by amplified FRET correlated with worse disease-free survival. Our findings support the use of amplified FRET to determine pAkt status in cancer tissues as candidate biomarker for the identification of high-risk patients.
Original language | English |
---|---|
Pages (from-to) | 4983-4995 |
Number of pages | 13 |
Journal | Cancer Research |
Volume | 74 |
Issue number | 18 |
DOIs | |
Publication status | Published - 15 Sep 2014 |
Keywords
- Biomarkers, Tumor/analysis
- Breast Neoplasms/enzymology
- Cell Line, Tumor
- Disease-Free Survival
- Female
- Fluorescence Resonance Energy Transfer/methods
- High-Throughput Screening Assays/methods
- Humans
- Prognosis
- Proto-Oncogene Proteins c-akt/analysis
Fingerprint
Dive into the research topics of 'High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer'. Together they form a unique fingerprint.Profiles
-
Banafshe Larijani
- Department of Life Sciences - Professor
- Centre for Therapeutic Innovation - Director
Person: Research & Teaching